Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study-Reference-Cited by-同舟云学术

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study

Published:2019-04-09 Issue:7 Volume:66 Page:e27736
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Braunstein Steve E.¹^ORCID,London Wendy B.²,Kreissman Susan G.³,Villablanca Judith G.⁴^ORCID,Davidoff Andrew M.⁵,DeSantes Kenneth⁶,Castleberry Robert P.⁷,Murray Kevin⁸,Diller Lisa⁹,Matthay Katherine¹⁰^ORCID,Cohn Susan L.¹¹,Shulkin Barry¹²^ORCID,Allmen Daniel¹³,Parisi Marguerite T.¹⁴,Ryn Collin¹⁵,Park Julie R.⁶,Quaglia Michael P.¹⁶,Haas‐Kogan Daphne A.¹⁷

Affiliation:

1. Department of Radiation OncologyUniversity of California San Francisco California

2. Department of Pediatric Oncology/HematologyBiostatistics DivisionDana‐Farber Cancer Institute, Boston Children's Hospital Boston Massachusetts

3. Department of PediatricsDuke University School of Medicine Durham North Carolina

4. Department of PediatricsKeck School of MedicineUniversity of Southern California Los Angeles California

5. Department of SurgeryPediatrics DivisionSt. Jude's Children's Research Hospital Memphis Tennessee

6. Department of PediatricsUniversity of WisconsinSchool of Medicine and Public Health Madison Wisconsin

7. Department of PediatricsUniversity of Alabama Medical Center Tuscaloosa Alabama

8. Department of PediatricsUniversity of Louisville Louisville Kentucky

9. Department of Pediatric Oncology/HematologyDana‐Farber Cancer Institute, Boston Children's Hospital Boston Massachusetts

10. Department of Pediatric Hematology‐OncologyUniversity of California San Francisco California

11. Department of PediatricsSection of Hematology/OncologyUniversity of Chicago Chicago Illinois

12. Department of Diagnostic ImagingPediatrics DivisionSt. Jude's Children's Research Hospital Memphis Tennessee

13. Department of Pediatric SurgeryCincinnati Children's Hospital Cincinnati Ohio

14. Department of RadiologyUniversity of WashingtonSeattle Children's Hospital Seattle Washington

15. Department of BiostatisticsUniversity of Florida Gainesville Florida

16. Department of Pediatric SurgeryMemorial Sloan Kettering Cancer Center New York New York

17. Department of Radiation OncologyDana‐Farber Cancer InstituteBrigham and Women's Hospital Boston Massachusetts

Funder

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27736

Reference21 articles.

1. Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study

2. Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

4. Advances in Risk Classification and Treatment Strategies for Neuroblastoma

5. Efficacy of complete resection for high-risk neuroblastoma: a children’s cancer group study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of High-Risk Neuroblastoma;Children;2023-07-28

2. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment;Cancers;2022-09-12

3. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes;American Society of Clinical Oncology Educational Book;2022-07

4. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project;Pediatric Blood & Cancer;2022-02-21

5. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study;Journal of Clinical Oncology;2020-09-01